Opinion|Videos|March 13, 2025

Overall Survival Benefit Update From RATIONALE-305

Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.


Latest CME